002219.SZ
Hengkang Medical Group Co.,Ltd [002219.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002219.SZ Stock Summary
Top 10 Correlated ETFs
002219.SZ
Top 10 Correlated Stocks
002219.SZ
In the News
002219.SZ Financial details
Company Rating
Strong Buy
Market Cap
12.01B
Income
162.25M
Revenue
3.24B
Book val./share
0.63
Cash/share
0.18
Dividend
-
Dividend %
-
Employees
7.82K
Optionable
No
Shortable
Yes
Earnings
29 Apr 2022
P/E
71.61
Forward P/E
-
PEG
-5.48
P/S
3.62
P/B
5.55
P/C
19.33
P/FCF
565.09
Quick Ratio
0.62
Current Ratio
0.7
Debt / Equity
0.78
LT Debt / Equity
0.36
-
-
EPS (TTM)
0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-123.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-3.86%
Revenue Q/Q
6.47%
EPS Q/Q
63.08%
-
-
-
-
SMA20
-0.28%
SMA50
-18.1%
SMA100
-26.61%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
9%
ROC
0.05%
Gross Margin
33%
Oper. Margin
4%
Profit Margin
5%
Payout
163%
Shs Outstand
3.38B
Shs Float
1.69B
-
-
-
-
Target Price
-
52W Range
3.41-5.88
52W High
-30.4%
52W Low
+16%
RSI
42.26
Rel Volume
0.86
Avg Volume
17.39M
Volume
14.99M
Perf Week
-2.79%
Perf Month
-8.42%
Perf Quarter
-30.26%
Perf Half Y
-30.82%
-
-
-
-
Beta
0.316821
-
-
Volatility
0.04%, 0.07%
Prev Close
-1.42%
Price
3.48
Change
1.46%
002219.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 2.06 | 1.97 | 1.5 | 1.62 | 0.97 | |
| Net income per share | -0.76 | -1.34 | -0.02 | -0.2 | 0.05 | |
| Operating cash flow per share | 0.28 | 0.29 | 0.15 | 0.15 | 0.08 | |
| Free cash flow per share | 0.16 | 0.18 | 0.04 | 0.04 | 0.01 | |
| Cash per share | 0.15 | 0.04 | 0.06 | 1.05 | 0.17 | |
| Book value per share | 1.45 | 0.1 | 0.07 | 0.83 | 0.53 | |
| Tangible book value per share | -0.43 | -0.58 | -0.59 | 0.23 | 0.19 | |
| Share holders equity per share | 1.45 | 0.1 | 0.07 | 0.83 | 0.53 | |
| Interest debt per share | 1.86 | 1.71 | 1.37 | 1.43 | 0.53 | |
| Market cap | 6.42B | 4.46B | 3.3B | 6.83B | 12.85B | |
| Enterprise value | 9.2B | 7.19B | 5.56B | 7.23B | 13.88B | |
| P/E ratio | -4.53 | -1.79 | -77.68 | -18.59 | 82.6 | |
| Price to sales ratio | 1.67 | 1.21 | 1.18 | 2.26 | 4.08 | |
| POCF ratio | 12.28 | 8.12 | 11.64 | 24.62 | 47.96 | |
| PFCF ratio | 21.24 | 13.36 | 49.13 | 86.91 | 276.64 | |
| P/B Ratio | 2.37 | 22.9 | 24.67 | 4.4 | 7.46 | |
| PTB ratio | 2.37 | 22.9 | 24.67 | 4.4 | 7.46 | |
| EV to sales | 2.4 | 1.95 | 1.98 | 2.4 | 4.4 | |
| Enterprise value over EBITDA | 238.77 | -31.95 | 15.07 | 22.8 | 26.46 | |
| EV to operating cash flow | 17.61 | 13.08 | 19.58 | 26.09 | 51.78 | |
| EV to free cash flow | 30.46 | 21.53 | 82.66 | 92.07 | 298.7 | |
| Earnings yield | -0.22 | -0.56 | -0.01 | -0.05 | 0.01 | |
| Free cash flow yield | 0.05 | 0.07 | 0.02 | 0.01 | 0 | |
| Debt to equity | 1.16 | 14.63 | 18.13 | 1.57 | 0.92 | |
| Debt to assets | 0.36 | 0.58 | 0.5 | 0.36 | 0.28 | |
| Net debt to EBITDA | 72.28 | -12.12 | 6.11 | 1.28 | 1.95 | |
| Current ratio | 0.77 | 0.27 | 0.29 | 0.66 | 0.54 | |
| Interest coverage | -3.77 | 0.35 | 1.45 | 0.67 | 2.51 | |
| Income quality | -0.38 | -0.22 | -6.68 | -0.75 | 1.63 | |
| Dividend Yield | 0.05 | 0.09 | 0.03 | 0.01 | 0.02 | |
| Payout ratio | -0.23 | -0.16 | -1.97 | -0.15 | 1.77 | |
| Sales general and administrative to revenue | 0.04 | 0.06 | 0.03 | 0.04 | 0.03 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.42 | 0.26 | 0.26 | 0.17 | 0.2 | |
| Capex to operating cash flow | -0.42 | -0.39 | -0.76 | -0.72 | -0.83 | |
| Capex to revenue | -0.06 | -0.06 | -0.08 | -0.07 | -0.07 | |
| Capex to depreciation | -0.96 | -1.6 | -1.27 | -1.22 | -1.33 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.99 | 1.77 | 0.19 | 1.92 | 0.75 | |
| ROIC | -0.23 | 0.04 | -0.33 | 0.04 | 0.09 | |
| Return on tangible assets | -0.28 | -0.69 | -0.01 | -0.07 | 0.03 | |
| Graham Net | -2.28 | -2.09 | -2.05 | -1.32 | -0.75 | |
| Working capital | -667.83M | -3.04B | -2.89B | -1.53B | -1.53B | |
| Tangible asset value | -801.92M | -1.08B | -1.1B | 427.92M | 615.68M | |
| Net current asset value | -3.6B | -3.56B | -3.46B | -2.08B | -2.08B | |
| Invested capital | 1.16 | 14.63 | 18.13 | 1.57 | 0.92 | |
| Average receivables | 1.8B | 1.24B | 850.26M | 811.47M | 920.17M | |
| Average payables | 606.2M | 729.79M | 852.98M | 937.6M | 1.08B | |
| Average inventory | 576.89M | 231.62M | 166.54M | 181.77M | 174.85M | |
| Days sales outstanding | 154.5 | 85.37 | 109.1 | 94.91 | 122.27 | |
| Days payables outstanding | 76.16 | 111.87 | 158.45 | 165.35 | 196.22 | |
| Days of inventory on hand | 37.38 | 20.83 | 32.29 | 30.62 | 27.78 | |
| Receivables turnover | 2.36 | 4.28 | 3.35 | 3.85 | 2.99 | |
| Payables turnover | 4.79 | 3.26 | 2.3 | 2.21 | 1.86 | |
| Inventory turnover | 9.76 | 17.52 | 11.3 | 11.92 | 13.14 | |
| ROE | -0.52 | -12.82 | -0.32 | -0.24 | 0.09 | |
| Capex per share | -0.12 | -0.12 | -0.12 | -0.11 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.38 | 0.4 | 0.25 | 0.23 | 0.25 | |
| Net income per share | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 | |
| Operating cash flow per share | 0.02 | 0.03 | 0.01 | 0.01 | 0.03 | |
| Free cash flow per share | 0.01 | 0 | 0 | -0.02 | 0.02 | |
| Cash per share | 0.58 | 0.32 | 0.17 | 0.23 | 0.18 | |
| Book value per share | 0.81 | 0.84 | 0.53 | 0.6 | 0.63 | |
| Tangible book value per share | 0.25 | 0.27 | 0.19 | 0.27 | 0.3 | |
| Share holders equity per share | 0.81 | 0.84 | 0.53 | 0.6 | 0.63 | |
| Interest debt per share | 0.92 | 0.88 | 0.5 | 0.53 | 0.49 | |
| Market cap | 6.62B | 7.34B | 12.85B | 16.66B | 15.13B | |
| Enterprise value | 7.25B | 8.43B | 13.88B | 17.63B | 16.1B | |
| P/E ratio | 33.67 | 29.67 | 74.05 | 193.08 | 106.78 | |
| Price to sales ratio | 8.71 | 9.12 | 15.56 | 21.41 | 18.27 | |
| POCF ratio | 134.68 | 118.69 | 296.19 | 772.31 | 173.85 | |
| PFCF ratio | 365.18 | 1.23K | -3.77K | -302.24 | 206.31 | |
| P/B Ratio | 4.13 | 4.41 | 7.46 | 8.3 | 7.23 | |
| PTB ratio | 4.13 | 4.41 | 7.46 | 8.3 | 7.23 | |
| EV to sales | 9.54 | 10.47 | 16.8 | 22.65 | 19.44 | |
| Enterprise value over EBITDA | 61.33 | 175.23 | 96.94 | 304.79 | 213.96 | |
| EV to operating cash flow | 147.42 | 136.27 | 319.81 | 817.06 | 185.01 | |
| EV to free cash flow | 399.73 | 1.42K | -4.07K | -319.75 | 219.55 | |
| Earnings yield | 0.01 | 0.01 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 1.11 | 1.04 | 0.92 | 0.87 | 0.78 | |
| Debt to assets | 0.29 | 0.31 | 0.28 | 0.3 | 0.28 | |
| Net debt to EBITDA | 5.3 | 22.6 | 7.16 | 16.69 | 12.9 | |
| Current ratio | 0.66 | 0.58 | 0.54 | 0.58 | 0.7 | |
| Interest coverage | 1.36 | 1.07 | 1.39 | 0.98 | 1.48 | |
| Income quality | 1 | 1 | 1 | 1 | 0 | |
| Dividend Yield | 0.01 | 0.03 | 0 | 0 | 0 | |
| Payout ratio | 0.78 | 3.27 | 0.45 | 1.05 | 0.58 | |
| Sales general and administrative to revenue | -0.09 | 0.34 | -0.26 | 0.17 | -0.02 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.19 | 0.21 | 0.2 | 0.2 | 0.19 | |
| Capex to operating cash flow | -0.63 | -0.9 | -1.08 | -3.56 | -0.16 | |
| Capex to revenue | -0.04 | -0.07 | -0.06 | -0.1 | -0.02 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.67 | 0.77 | 0.4 | 0.3 | 0.39 | |
| ROIC | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
| Graham Net | -1.27 | -1.19 | -0.75 | -0.65 | -0.65 | |
| Working capital | -1.22B | -1.26B | -1.53B | -1.4B | -865.3M | |
| Tangible asset value | 490.48M | 534.92M | 615.68M | 901.59M | 992.35M | |
| Net current asset value | -2.1B | -2.03B | -2.08B | -1.82B | -1.73B | |
| Invested capital | 1.11 | 1.04 | 0.92 | 0.87 | 0.78 | |
| Average receivables | 864.55M | 911.92M | 988.2M | 1.03B | 1.1B | |
| Average payables | 1.02B | 1.02B | 1.1B | 1.16B | 1.19B | |
| Average inventory | 179.92M | 176.53M | 172.16M | 166.93M | 165.27M | |
| Days sales outstanding | 106.94 | 102.86 | 115.06 | 115.67 | 130.51 | |
| Days payables outstanding | 177.84 | 160.49 | 208.33 | 190.97 | 206.41 | |
| Days of inventory on hand | 30.52 | 28.05 | 29.5 | 28.02 | 27.05 | |
| Receivables turnover | 0.84 | 0.87 | 0.78 | 0.78 | 0.69 | |
| Payables turnover | 0.51 | 0.56 | 0.43 | 0.47 | 0.44 | |
| Inventory turnover | 2.95 | 3.21 | 3.05 | 3.21 | 3.33 | |
| ROE | 0.03 | 0.04 | 0.03 | 0.01 | 0.02 | |
| Capex per share | -0.02 | -0.03 | -0.01 | -0.02 | 0 |
002219.SZ Frequently Asked Questions
What is Hengkang Medical Group Co.,Ltd stock symbol ?
Hengkang Medical Group Co.,Ltd is a CN stock and trading under the symbol 002219.SZ
What is Hengkang Medical Group Co.,Ltd stock quote today ?
Hengkang Medical Group Co.,Ltd stock price is $3.48 today.
Is Hengkang Medical Group Co.,Ltd stock public?
Yes, Hengkang Medical Group Co.,Ltd is a publicly traded company.
Company Profile
- Volume Average 17.39M
- Market Capitalization 12.01B
- Employee 7.82K
- CEO Mr. Liu Jun
- Headquarters Chengdu,CN
- IPO Date 2008-03-06
-
Website
https://www.hkmg.com 
Hengkang Medical Group Co.,Ltd provides medical services, pharmaceuticals, health care, and daily chemical products in China and internationally. It operates approximately 11 hospitals. The company also manufactures pharmaceutical products in the areas of analgesia, cold, cough, gynecology, cardiovascular, digestive, and urinary systems. In addition, it offers Chinese herbal medicines, infusion, and hemostasis products, as well as daily chemical products. The company was formerly known as Gansu Duyiwei Biological Pharmaceutical Co., Ltd. and changed its name to Hengkang Medical Group Co.,Ltd in January 2014. Hengkang Medical Group Co.,Ltd. was founded in 2001 and is based in Chengdu, China.
